United Therapeutics Valuation
| UTHR Stock | USD 312.99 0.61 0.19% |
At this time, the company appears to be undervalued. United Therapeutics has a current Real Value of $336.7 per share. The regular price of the company is $312.99. Our model measures the value of United Therapeutics from inspecting the company fundamentals such as Shares Outstanding of 44.91 M, operating margin of 0.49 %, and Return On Equity of 0.19 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting United Therapeutics' valuation include:
Price Book 2.2223 | Enterprise Value | Enterprise Value Ebitda 6.8625 | Price Sales 4.8949 | Forward PE 11.5473 |
Undervalued
Today
Please note that United Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of United Therapeutics is based on 3 months time horizon. Increasing United Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the United stock is determined by what a typical buyer is willing to pay for full or partial control of United Therapeutics. Since United Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of United Stock. However, United Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 312.99 | Real 336.7 | Target 398.02 | Hype 313.1 | Naive 332.18 |
The intrinsic value of United Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence United Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of United Therapeutics helps investors to forecast how United stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of United Therapeutics more accurately as focusing exclusively on United Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use United Therapeutics' intrinsic value based on its ongoing forecasts of United Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against United Therapeutics' closest peers.
United Therapeutics Cash |
|
United Valuation Trend
United Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of United Therapeutics' financial worth over time. Using both United Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
United Revenue by Product
United Therapeutics Total Value Analysis
United Therapeutics is at this time forecasted to have valuation of 11.35 B with market capitalization of 14.08 B, debt of 300 M, and cash on hands of 2.26 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the United Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
11.35 B | 14.08 B | 300 M | 2.26 B |
United Therapeutics Investor Information
About 98.0% of the company outstanding shares are owned by institutional investors. The book value of United Therapeutics was at this time reported as 143.74. The company has Price/Earnings To Growth (PEG) ratio of 1.43. United Therapeutics recorded earning per share (EPS) of 24.65. The entity had not issued any dividends in recent years. The firm had 2:1 split on the 23rd of September 2009. Based on the key indicators related to United Therapeutics' liquidity, profitability, solvency, and operating efficiency, United Therapeutics is performing exceptionally good at this time. It has a great odds to report excellent financial results in April.United Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. United Therapeutics has an asset utilization ratio of 39.07 percent. This connotes that the Company is making $0.39 for each dollar of assets. An increasing asset utilization means that United Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.United Therapeutics Ownership Allocation
The majority of United Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in United Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in United Therapeutics. Please pay attention to any change in the institutional holdings of United Therapeutics as this could imply that something significant has changed or is about to change at the company.United Therapeutics Profitability Analysis
The company reported the previous year's revenue of 2.88 B. Net Income was 1.2 B with profit before overhead, payroll, taxes, and interest of 2.57 B.About United Therapeutics Valuation
The stock valuation mechanism determines United Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of United Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of United Therapeutics. We calculate exposure to United Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of United Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 2.6 B | 2.7 B | |
| Pretax Profit Margin | 0.53 | 0.56 | |
| Operating Profit Margin | 0.48 | 0.50 | |
| Net Profit Margin | 0.42 | 0.44 | |
| Gross Profit Margin | 0.89 | 0.58 |
United Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as United Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 48.5 M | |
| Quarterly Earnings Growth Y O Y | 0.421 | |
| Forward Price Earnings | 11.5473 |
United Therapeutics Current Valuation Indicators
United Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final United Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as United Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use United Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes United Therapeutics' worth.Additional Tools for United Stock Analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.